Smith & Nephew SNATS (NYSE:SNN) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $31.06 and traded as high as $32.66. Smith & Nephew SNATS shares last traded at $32.4660, with a volume of 2,679,835 shares traded.

Wall Street Analyst Weigh In

SNN has been the subject of a number of recent research reports. Weiss Ratings cut shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Zacks Research upgraded shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th. Bank of America lowered Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a report on Tuesday, September 8th. Finally, Barclays cut Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.91.

Smith & Nephew SNATS Trading Up 7.6%

The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. The company’s 50 day moving average price is $28.41 and its two-hundred day moving average price is $31.06.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its position in shares of Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares during the period. Clearstead Trust LLC bought a new position in shares of Smith & Nephew SNATS in the second quarter worth about $25,000. Versant Capital Management Inc grew its position in shares of Smith & Nephew SNATS by 7.9% during the third quarter. Versant Capital Management Inc now owns 8,852 shares of the medical equipment provider’s stock worth $239,000 after purchasing an additional 647 shares in the last quarter. Addison Advisors LLC bought a new stake in shares of Smith & Nephew SNATS during the second quarter valued at approximately $43,000. Finally, Allworth Financial LP purchased a new position in shares of Smith & Nephew SNATS in the second quarter worth $48,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.